There has been much debate about whether there is a global deterioration of IP, and many commentators would suggest that India is leading the charge. Andrew Jenner and Ernest Kawka reflect on the experiences of innovative biopharmaceutical companies in India.
In late 2011, India adopted a National Manufacturing Policy to boost gross domestic product from 16 percent to 25 percent by 2022. The policy aims to aggressively increase domestic manufacturing capacity, especially in high technology areas.
One mechanism to achieve this goal is by adopting measures that “ensure access for Indian companies to foreign technologies” by “leveraging the strength of India’s large market”. The official policy further elaborates that one way to ensure access to foreign technologies requires India to overhaul its IP regime “to enable more collaborative innovation.”
During the 2012 general assemblies of the World Intellectual Property Organization (WIPO), India proclaimed that “while fully recognising the importance of IP rights for innovation—diffusion of technology also merits serious consideration.”
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at firstname.lastname@example.org.
If you have any technical issues please email tech support.
India, biopharma, deterioration of IP, biopharma innovation, compulsory licences